



2014 Inpatient Cumulative Antibigram

Microbiology Section
Division of Laboratory Medicine, Marshfield Clinic
Marshfield Wisconsin

Contact Dr. Thomas Novicki or Dr. Thomas Fritsche at ext. 16300 (715-221-6300) for additional information regarding this report. Contact the Saint Joseph's Hospital Pharmacy at ext. 77687 (715-387-7687) for dosing and other drug information.

Gram Negative % Susceptible	<i>Enterobacter cloacae</i>	<i>Escherichia coli</i>	<i>Haemophilus influenza (1)</i>	<i>Klebsiella pneumoniae</i>	<i>Proteus mirabilis</i>	<i>Pseudomonas aeruginosa</i>	<i>Stenotrophomonas maltophilia (1)</i>
Maximum # tested	22	177	75	59	25	113	64
Amikacin	100%	100%	-	100%	100%	99%	-
Ampicillin	0%	57%	71% (2)	0%	52%	-	-
Ampicillin/ Sulbactam	23%	66%	-	88%	100%	-	-
Aztreonam	77%	92%	-	97%	100%	82%	-
Cefazolin	0%	71%	-	86%	4%	-	-
Cefepime	95%	99%	-	98%	100%	91%	-
Ceftazidime	77%	94%	-	98%	100%	94%	66%
Ceftriaxone	73%	87%	-	97%	100%	-	-
Ciprofloxacin	95%	71%	-	93%	64%	87%	-
Gentamicin	95%	93%	-	97%	76%	98%	-
Imipenem	100%	100%	-	100%	88%	96%	-
Levofloxacin	95%	71%	-	95%	68%	83%	77%
Meropenem	100%	100%	-	100%	100%	98%	-
Nitrofurantoin	70%	99%	-	95%	0%	-	-
Piperacillin/ Tazobactam	82%	97%	-	98%	100%	95%	-
Tetracycline	82%	79%	-	81%	0%	0%	-
Ticarcillin/ Clavulanic Acid	77%	81%	-	88%	100%	85%	64%
Tobramycin	95%	95%	-	95%	84%	98%	-
Trimethoprim/ Sulphamethoxazole	95%	80%	-	86%	80%	-	100%

Footnotes

-, data not available.

(1) Marshfield Clinic and Ministry St. Joseph's Hospital (Marshfield WI) combined data.

(2) Ampicillin susceptibility predicted from a negative beta-lactamase test.

Gram Positive % Susceptible	Enterococcus sp.	Staphylococcus aureus	Staphylococcus, coagulase- negative group	Streptococcus anginosus group	Streptococcus pneumoniae (1)
Maximum # tested	304	494	281	29	63
Ampicillin	80%	-	-	-	-
Ceftriaxone	-	-	-	100%	-
Ceftriaxone M (2)	-	-	-	-	86%
Ceftriaxone NM (3)	-	-	-	-	98%
Clindamycin	-	62%	46%	78%	-
Daptomycin	100%	100%	100%	100%	-
Erythromycin	14%	45%	7%	68%	49%
Gentamicin	-	97%	74%	-	-
Gentamicin synergy (4)	65%	-	-	-	-
Levofloxacin	47%	62%	44%	100%	98%
Linezolid	100%	100%	100%	100%	-
Nitrofurantoin	96%	100%	100%	-	-
Oxacillin (5)	-	63%	34%	-	-
Penicillin	-	16%	19%	97%	-
Penicillin M&O (6)	-	-	-	-	65%
Penicillin NM (7)	-	-	-	-	96%
Tetracycline	19%	88%	89%	73%	89%
Trimethoprim/ Sulphamethoxazole	-	98%	61%	-	92%
Vancomycin	84%	100%	100%	100%	100%

Footnotes

-, data not available or clinically unproven, or intrinsically resistant.

(1) Marshfield Clinic and Ministry St. Joseph's Hospital (Marshfield WI) combined data.

(2) Based on **meningeal** breakpoint of ≤ 0.5 mcg/mL = susceptible. Primarily penicillin non-susceptible isolates tested.

(3) Based on **non-meningeal** breakpoint of ≤ 1 mcg/mL = susceptible. Primarily penicillin non-susceptible isolates tested.

(4) Gentamicin Synergy, synergistic action is predicted when co-treated with a cell wall-active agent (ampicillin or vancomycin) and gentamicin **when the isolate is susceptible to both agents.**

(5) Oxacillin/methicillin susceptible=susceptible to anti-staphylococcal penicillins (e.g. cloxacillin, nafcillin), cephalosporins, beta lactam/beta lactamase inhibitor antimicrobials, and carbapenems.

(6) Based on **oral/meningeal** breakpoints of ≤ 0.06 mcg/mL = susceptible.